DSpace Repository

Advances in Treatment of Frontotemporal Dementia

Show simple item record

dc.contributor.author Magrath Guimet, Nahuel
dc.contributor.author Zapata-Restrepo, Lina M.
dc.contributor.author Miller, Bruce L.
dc.date.accessioned 2022-11-10T12:24:47Z
dc.date.available 2022-11-10T12:24:47Z
dc.date.issued 2022
dc.identifier.citation Magrath Guimet N, Zapata-Restrepo LM, Miller BL. Advances in Treatment of Frontotemporal Dementia. J Neuropsychiatry Clin Neurosci. 2022 Fall;34(4):316-327. doi: 10.1176/appi.neuropsych.21060166. Epub 2022 May 17. es_ES
dc.identifier.uri https://repositorio.fleni.org.ar/xmlui/handle/123456789/716
dc.identifier.uri https://doi.org/10.1176/appi.neuropsych.21060166
dc.description.abstract In this review, the authors explored the clinical features of frontotemporal dementia (FTD), focusing on treatment. The clinical features of FTD are unique, with disinhibition, apathy, loss of empathy, and compulsions common. Motor changes occur later in the illness. The two major proteins that aggregate in the brain with FTD are tau and TDP-43, whereas a minority of patients aggregate FET proteins, primarily the FUS protein. Genetic causes include mutations in MAPT, GRN, and C9orf72. There are no medications that can slow FTD progression, although new therapies for the genetic forms of FTD are moving into clinical trials. Once a diagnosis is made, therapies should begin, focusing on the family and the patient. In the setting of FTD, families experience a severe burden associated with caregiving, and the clinician should focus on alleviating this burden. Advice around legal and financial issues is usually helpful. Careful consideration of environmental changes to cope with abnormal behaviors is essential. Most compounds that have been used to treat dementia of the Alzheimer's disease type are not effective in FTD, and cholinesterase inhibitors and memantine should be avoided. Although the data are scant, there is some evidence that antidepressants and second-generation antipsychotics may help individual patients. es_ES
dc.language.iso eng es_ES
dc.publisher American Psychiatric Press es_ES
dc.rights info:eu-repo/semantics/openAccess
dc.rights.uri https://creativecommons.org/licenses/by/2.5/ar/
dc.subject Dementia es_ES
dc.subject Demencia es_ES
dc.subject Psicoterapia es_ES
dc.subject Psychotherapy es_ES
dc.title Advances in Treatment of Frontotemporal Dementia es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.type info:eu-repo/semantics/publishedVersion
dc.description.fil Fil: Magrath Guimet, Nahuel. Fleni. Departamento de Neurología. Servicio de Neurología Cognitiva, Neuropsicología y Neuropsiquiatría; Argentina. University of California; Estados Unidos.
dc.description.fil Fil: Zapata-Restrepo, Lina M. University of California; Estados Unidos. Pontifical Xaverian University Cali; Colombia.
dc.description.fil Fil: Miller, Bruce L. University of California. Weill Institute for Neuroscience. Department of Neurology, Memory and Aging Center; Estados Unidos.
dc.relation.ispartofVOLUME 34
dc.relation.ispartofNUMBER 4
dc.relation.ispartofPAGINATION 316-327.
dc.relation.ispartofCOUNTRY Estados Unidos
dc.relation.ispartofCITY Arlington
dc.relation.ispartofTITLE The Journal of neuropsychiatry and clinical neuroscience
dc.relation.ispartofISSN 1545-7222
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess

Search DSpace


Browse

My Account

Statistics